- Home
- NML vs PRLD Comparison
NML vs PRLD Comparison
Compare NML & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NML | PRLD |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.4M | 529.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NML | PRLD |
|---|---|---|
| Price | $10.68 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 145.9K | ★ 531.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $7.89 | $0.98 |
| 52 Week High | $10.98 | $6.83 |
Technical Indicators
Market Signals| Indicator | NML | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 37.15 |
| Support Level | $9.65 | $3.92 |
| Resistance Level | $10.92 | $4.69 |
| Average True Range (ATR) | 0.24 | 0.40 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 74.24 | 4.07 |
Price Performance
Historical ComparisonAbout NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.